FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know On April 15, 2026, the FDA announced a significant regulatory update: injectable GHK-Cu (copper tripeptide-1) will be removed from the Category 2 bulk substances list by July 2026
Presently, there is no definitive cure
For those looking for a more direct approach, professional Peptide Therapy can introduce these powerful compounds systemically for comprehensive benefits
For women experiencing menopause, hormone replacement therapy can help restore hormonal balance, reduce abdominal fat, and improve metabolism
Lead Researcher Spotlight Professor Ania M
Remove the needle at the same angle, then apply gentle pressure to the site with a clean cotton pad or gauze for a few seconds